Stuart W. Titus, PhD, President and CEO of Medical Marijuana Inc. mentions: "We are extremely excited to announce our strategic ownership interest in AXIM Biotech and explain to MJNA’s shareholders some of the important innovations that Dr. Anastassov and the AXIM team are focused on.
AXIM Biotech’s recent announcements include hemp-based innovations that provide consumers a wide variety of new options worldwide."
AXIM Biotech is a unique biotechnology company focused on global research, development and production of pharmaceutical, food, nutraceutical and cosmetic products as well as biofuels derived from cannabinoids. AXIM Biotech is focusing its efforts on unique proprietary mechanisms for the delivery of cannabinoids (e.g. CBD, CBG, etc.).
George E. Anastassov, MD, DDS, MBA and CEO of AXIM Biotech states, "AXIM is a unique hemp-derived biosciences corporation where the responsibility for environmental protection and conservation meets the passion for development of innovative biotechnological applications for problems for which there are currently no solutions.
The cannabis plant provides ample opportunity for innovative, sometimes revolutionary products. AXIM has realized the vast potential in oral health products based on cannabinoids, in particular CBG, and has filed intellectual property applications to protect its numerous IP."
AXIM Biotech recently announced that it is the exclusive license recipient to the world’s first controlled-release cannabinoid chewing gum.
This opens two markets for product development and distribution: food with CanChew Plus and pharmaceutical with MedChew RX, which is undergoing clinical trials in preparation for registration with FDA and EMA.
The Company also recently unveiled the world’s first oral care and cosmetic lines, Oraximax and Renecann, containing cannabigerol (CBG).
The global pharmaceutical market is reported to be potentially worth nearly $1.6 trillion by 2020. AXIM Biotech intends to develop innovative pharmaceutical delivery systems and API (active pharmaceutical ingredients) for treatment of conditions such as Parkinson’s disease, Alzheimer’s disease, ADHD (attention deficit hyperactivity disorder), PTSD, autism, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBS, IBD, Crohn’s disease and more.
All of these efforts are based on proprietary IP.
Additional markets where AXIM Biotech intends to play a significant role are:
– Nutraceutical — Global Potential $207 Billion by 2016
– Phytoplant/Botanicals — Global Current Market $83 Billion
– R&D — Drug Discovery a Global $25 Billion Market
– Alternative Energy — Global Biofuels $185.3 Billion by 2021
– Manufacturing — 16% of Global GDP and Growing
Leading AXIM Biotechnologies is an international executive team of highly skilled and specialized professionals. Its members are responsible for the Company’s strategic initiatives and global operations.
Through various committees, they oversee operations and business performance, strategy and planning, future and current product manufacturing, risk management, research and development, external affairs, and internal governance.